In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.

The free consultation period for this content is over.

It is now only available year-round to ESC Professional Members, Fellows of the ESC, and Young combined Members

Day-to-day home monitoring of heart rate as a predictor of imminent cardiovascular events.

Session Poster session 2

Speaker Antti Kiviniemi

Congress : ESC Congress 2017

  • Topic : basic science
  • Sub-topic : Basic Science - Cardiac Biology and Physiology
  • Session type : Poster Session
  • FP Number : P1575

Authors : MP Tulppo (oulu,FI), M Lahtinen (oulu,FI), JJ Karjalainen (oulu,FI), AM Kiviniemi (oulu,FI), AJ Hautala (oulu,FI), HV Huikuri (oulu,FI)


M.P. Tulppo1 , M. Lahtinen1 , J.J. Karjalainen1 , A.M. Kiviniemi1 , A.J. Hautala1 , H.V. Huikuri1 , 1Research Unit of Internal Medicine - Oulu - Finland ,

European Heart Journal ( 2017 ) 38 ( Supplement ), 334

Background: Previous studies have shown an association between day-to-day variability of heart rate (HR) and cardiovascular (CV) events in general population. This association is unknown in coronary artery disease (CAD) patients with optimal medical therapy.

Purpose: To study HR and HR variability dynamics at home before the occurrence of CV events.

Methods: A total of 160 angiographically documented CAD patients from ARTEMIS study were guided into 2-years home- based exercise intervention and 44 patients (age 61±5 years, BMI 29±4, LVEF 66±7% and maximal exercise capacity 161±43 W) were willing to measure R-R intervals on a weekly basis at home during the follow-up. Eleven out of 44 patients had a new onset of ACS (n7), cardiac death (n=1), new onset of arrhythmia needing hospitalization (n=2), or stroke (n=1) during the follow-up. Day-to-day HR and HR variability (SDANN) were analyzed prospectively from weekly home measurements for 8 weeks preceding the CV event or from corresponding period without the event. Home measurements were performed in controlled conditions including 3 min beat-to-beat R-R intervals recordings in sitting and supine positions.

Results: There were no differences in the mean HR or SDANN analyzed over 8 weeks between the groups, e.g. the mean R-R interval at sitting position was 1000±138 vs. 1020±156 ms and SDANN 38±12 vs. 39±14 ms (p=ns for both) for patients without and with the new onset of event, respectively. During the 8-week period preceding the CV event, the day-to-day variability of mean R-R intervals was larger in patients with the new onset of event compared to patient without the event in the supine (87±19 vs. 62±7 ms, p=0.009) and sitting positions (93±24 vs. 65±7 ms, p=0.013), respectively. The day-to-day variability of SDANN did not differ between the groups, e.g. 12±6 vs 15±8 ms in patients without and with a new onset of event in the sitting position, respectively. There were no differences in age, BMI, LVEF or exercise capacity between the groups.

Conclusions: These data show that day-to-day variability of HR increases before the onset of CV events suggesting to a more unstable hemodynamic balance preceding these events. If confirmed in a large sample size, home HR measurement may become a simple and useful method for providing information on the risk of imminent CV event in patients with stable CAD.

Mean R-R intervals in two patients

The free consultation period for this content is over.

It is now only available year-round to ESC Professional Members, Fellows of the ESC, and Young combined Members

Based on your interests

Three reasons why you should become a member

Become a member now
  • 1Access your congress resources all year-round on the New ESC 365
  • 2Get a discount on your next congress registration
  • 3Continue your professional development with free access to educational tools
Become a member now

Our sponsors

ESC 365 is supported by Bayer, Boehringer Ingelheim, Bristol-Myers Squibb and Pfizer Alliance, and Novartis Pharma AG. The sponsors were not involved in the development of this platform and had no influence on its content.

logo esc

Our mission: To reduce the burden of cardiovascular disease

Who we are